United States Drug Patent 5,998,402: Claim Scope, Bazedoxifene Coverage, Expiration and Patent Landscape

U.S. Patent No. 5,998,402 covers a broad genus of substituted 1-benzylindole compounds, including bazedoxifene and multiple salts, esters, analogs and tertiary-amine variants. The patent also claims pharmaceutical compositions and treatment of bone loss. Its commercial relevance is tied primarily to bazedoxifene products, including Viviant and the bazedoxifene/conjugated-estrogen combination Duavee. The patent is an old small-molecule patent, not a biologic patent, so biosimilar law is inapplicable. Any current exclusivity analysis must distinguish the patent's original term from later patents, regulatory exclusivity and any patent-term extension.

What drug does U.S. Patent 5,998,402 protect?

The patent protects a family of selective estrogen receptor modulator, or SERM, compounds based on a substituted indole nucleus. The central structural pattern is:

a 1-benzyl-substituted indole;
a 2-aryl substituent;
a 3-substituent, most often methyl;
a 5-substituent, often hydroxy or benzyloxy; and
a para-substituted benzyl side chain bearing a 2-aminoethoxy or 3-aminopropoxy group.

The claims expressly cover compounds corresponding to bazedoxifene. The principal commercial compound is commonly identified as:

bazedoxifene;
bazedoxifene acetate;
1-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol.

The supplied claims use "azepan" terminology for the seven-membered nitrogen heterocycle. Claim 44 is directed to the hydrochloride form of the azepane analog, while claim 45 addresses the acetate salt. Claim 46 covers the corresponding azocane analog, which has a larger saturated nitrogen ring.

FDA approved bazedoxifene as Viviant for postmenopausal osteoporosis in women at high risk of fracture. FDA later approved Duavee, which combines conjugated estrogens and bazedoxifene for menopausal vasomotor symptoms and prevention of postmenopausal osteoporosis [2][3].

How broad are the independent claims?

Claims 1, 3 and 4 are broad composition-of-matter claims. They cover formulas I and II with extensive substituent variation. The principal variables are:

Claim variable	Covered options
R1	Hydrogen, hydroxyl, alkoxy, acyloxy, halogen and halogenated ether groups
R2-R6	Hydrogen, hydroxyl, alkoxy, acyloxy, halogen, cyano, alkyl and trifluoromethyl
X	Hydrogen, alkyl, cyano, nitro, trifluoromethyl or halogen
n	Two or three carbon atoms
R7/R8	Hydrogen, alkyl or substituted phenyl
Nitrogen ring	Pyrrolidine, piperidine, azepane, azocane and bridged or fused bicyclic amines
Salt form	Pharmaceutically acceptable salts

The broadest commercial significance comes from the combination of two substituent families:

variation around the indole and 2-aryl groups; and
variation in the terminal tertiary amine, including piperidine, azepane, pyrrolidine and bicyclic amines.

This drafting approach creates a large Markush genus. A competing compound may fall within the claim even if it differs from bazedoxifene at the aryl substituent, the indole 5-position, the side-chain length or the terminal amine.

What chemical features are essential to infringement?

For a compound to fall within the broad composition claims, the relevant structure must satisfy the claimed indole framework and each applicable substituent limitation. The following elements are particularly important:

the indole ring system;
substitution at the indole nitrogen through a benzyl group;
an aryl group at the indole 2-position;
a permitted group at the indole 3-position;
the claimed oxygen-linked aminoalkyl side chain; and
a permitted tertiary or secondary amine configuration.

A simple change from a 2-carbon linker to a 3-carbon linker may remain covered because claims 1, 3 and 4 permit n=2 or 3. A different ring size may also remain covered if it falls within the specified heterocyclic categories. By contrast, replacement of the indole core with a benzothiophene, benzofuran or triphenylethylene core would generally move outside the literal scope of these claims.

Which claims specifically cover bazedoxifene?

The most commercially relevant species claims are claims 44 and 45, read with claim 1.

Claim 44 recites:

a 2-(4-hydroxyphenyl) group;
a 3-methyl indole;
a 5-hydroxy group;
a benzyl-linked 2-azepane-1-yl ethoxy substituent; and
the hydrochloride salt.

Claim 45 covers the same core azepane compound as an acetate salt. Bazedoxifene is generally administered as bazedoxifene acetate, making claim 45 particularly relevant to the marketed active pharmaceutical ingredient.

Claim 102 separately recites the piperidine analog. Claims 53 through 60 cover substituted piperidine and bicyclic analogs. Claims 61 through 77 cover aryl and heteroaryl modifications, while claims 78 through 90 expand coverage to chloro, ethyl and cyano indoles.

The patent therefore contains both:

genus claims capable of reaching many analogs; and
species claims directed to identifiable development candidates.

What do claims 6 through 104 add?

Claims 6 through 104 are mostly dependent species claims. They enumerate specific compounds rather than functional categories. The species include:

benzyloxy-protected compounds;
hydroxy and methoxy analogs;
piperidine, pyrrolidine and azepane compounds;
methyl-substituted piperidines;
dimethyl, diethyl, dipropyl and dibutyl aminoethyl variants;
bridged bicyclic amines;
methiodide salts;
hydrochloride salts;
acetate salts;
dipropionate and dipivalate prodrugs or ester derivatives; and
3-aminopropoxy analogs.

The species claims strengthen the patent's written record for particular compounds and salt forms. They also create multiple potential claim-construction issues because several chemical names contain apparent typographical defects, including inconsistent punctuation, missing ring descriptors and nonstandard expressions such as "2-dimethyl-1-yl-ethoxy."

Under U.S. patent law, the issued claim text, specification, prosecution history and any certificate of correction govern. A chemical-name error does not automatically invalidate a claim if the structure is clear from the drawings and specification. If the error makes the claimed compound insolubly ambiguous, indefiniteness and written-description arguments become more plausible.

What formulation and salt forms are protected?

The patent is principally a compound patent, not a modern pharmaceutical-formulation patent. Claim 105 covers a pharmaceutical composition comprising a claimed compound or salt and a pharmaceutically acceptable carrier or excipient.

The patent expressly reaches several salt and derivative categories:

hydrochloride salts;
acetate salts;
methiodide salts;
dipropionate esters;
dipivalate esters; and
other pharmaceutically acceptable salts within the Markush language.

Claim 45 is the most important salt claim for bazedoxifene acetate. A generic manufacturer using the same bazedoxifene acetate active ingredient would face composition-of-matter issues if the claim remained enforceable. A formulation using a different crystal form, particle-size distribution or excipient system would not necessarily avoid a live compound claim because the compound claim does not depend on the dosage-form architecture.

Claim 105 has narrower practical value. It requires a composition containing a claimed compound, but conventional tablets, capsules and oral suspensions would generally satisfy the carrier or excipient limitation.

What method-of-use claims are included?

Claim 106 covers administering a claimed compound to treat or prevent bone loss in a mammal. The method is broad in several respects:

it is not limited to women;
it is not limited to postmenopausal osteoporosis;
it does not specify a dose;
it does not specify a route of administration; and
it does not require a particular fracture-risk profile.

The claim could reach treatment or prevention of osteoporosis and other bone-loss conditions if the compound is administered for that purpose. It is weaker against a generic product sold with a label that omits the patented indication, but induced-infringement analysis would depend on labeling, marketing, prescribing information and the product's reasonably foreseeable uses.

The patent does not, based on the supplied claims, claim the later Duavee combination as a specific combination product. Combination, dosing, regimen and menopausal-symptom claims must be analyzed separately in the later Duavee patent family and FDA Orange Book records.

When did U.S. Patent 5,998,402 lose exclusivity?

The patent issued on December 7, 1999 [1]. Its term is governed by the post-1995 twenty-year rule, measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any patent-term extension.

Public patent records identify the relevant priority and filing history as dating to the mid-1990s. On that basis, the ordinary term would have ended in the mid-2010s or, depending on the effective filing date and adjustments, around 2017. The original patent should therefore be treated as expired unless an official term-extension record establishes otherwise.

Event	Date or period
Earliest patent-family activity	Mid-1990s
U.S. filing period	1997
Patent issued	Dec. 7, 1999
Ordinary twenty-year term	Mid-2010s to approximately 2017
Current practical status	Original patent term has ended or is no longer the principal barrier

The key commercial point is that a current bazedoxifene entry analysis cannot rely on U.S. Patent 5,998,402 alone. Any remaining barrier would more likely arise from later patents, listed combination-product patents, regulatory exclusivity, pending litigation or settlement restrictions.

What is the Orange Book status of the patent?

The Orange Book is product-specific. A patent can be relevant to the same active ingredient without being listed for every product containing that ingredient. The relevant products include:

Viviant, bazedoxifene acetate monotherapy;
Duavee, conjugated estrogens and bazedoxifene; and
products approved outside the United States, including European bazedoxifene products.

For an ANDA applicant, a listed patent creates the potential for a Paragraph IV certification. If the patent has expired, the applicant may instead certify that the patent is expired or provide another certification permitted by FDA rules. A Paragraph IV notice against an expired patent would not create the same litigation or thirty-month-stay consequences as a challenge to an unexpired listed patent.

Bazedoxifene is a small molecule. The Purple Book biosimilar framework does not apply. A generic applicant would use the ANDA pathway under section 505(j), subject to bioequivalence, pharmaceutical-equivalence and labeling requirements [4][5].

Which companies are challenging bazedoxifene exclusivity?

The supplied record does not identify a particular ANDA, Paragraph IV notice, litigation docket or settlement agreement. No company-specific challenger, launch date or settlement term can be assigned from the claim text alone.

The relevant competitive set is:

Competitor type	Applicable pathway	Principal issue
Generic bazedoxifene acetate	ANDA	Bioequivalence, salt form, Orange Book patents
Generic bazedoxifene/conjugated-estrogen combination	ANDA or 505(b)(2), depending on product	Combination equivalence and listed patents
SERM alternative	Full or abbreviated small-molecule pathway	Clinical differentiation and separate patent estate
Biosimilar	Not applicable	Bazedoxifene is not a biologic

Potential generic design-around strategies would include a different salt, polymorph, formulation or manufacturing process. Those approaches would not necessarily avoid an active ingredient claim covering bazedoxifene itself.

How strong is the patent estate?

Composition-of-matter strength

The composition claims are structurally strong against exact bazedoxifene or close claimed analogs if still enforceable. Composition claims generally provide broader protection than method or formulation claims because they do not depend on a particular use.

The principal vulnerabilities are:

prior-art genus disclosure;
enablement across the very large Markush scope;
written description for remote analogs;
indefiniteness caused by chemical nomenclature defects;
prosecution-history narrowing; and
expiration.

Species-claim strength

Claims 44 and 45 are materially narrower and easier to map to a commercial compound. Their strength depends on whether the exact stereochemistry, salt, hydration state and structural representation match the marketed product.

Method-claim strength

Claim 106 is broad but commercially more dependent on the approved label and promotional conduct. It would be less effective against a product with a carefully limited non-bone-loss indication, although induced-infringement exposure could remain.

Formulation-claim strength

Claim 105 is conventional and comparatively weak as a standalone barrier. It does not require a distinctive release profile, excipient ratio, particle size, polymorph or manufacturing step.

What manufacturing and IP barriers remain?

The patent does not claim a detailed manufacturing process in the supplied claims. A manufacturer could therefore face process and intermediate patents elsewhere in the family or in separate families, but those rights cannot be inferred from U.S. Patent 5,998,402.

The practical barriers for a generic manufacturer are:

establishing access to a commercially viable bazedoxifene acetate process;
demonstrating impurity control and stereochemical consistency;
qualifying the appropriate salt or solid form;
satisfying FDA bioequivalence requirements;
clearing any unexpired Orange Book patents; and
addressing combination-product patents for Duavee.

Geographic coverage is jurisdiction-specific. Expiration of the U.S. patent does not determine the status of corresponding European, Canadian, Japanese or other national patents. Each counterpart requires a separate term, opposition and litigation review.

How does this patent compare with competing SERM patent estates?

Product or class	Core chemistry	Patent risk profile
Bazedoxifene	Substituted indole SERM	Exact compound protection, later product and combination patents
Raloxifene	Benzothiophene SERM	Separate composition and formulation estate
Toremifene	Triphenylethylene SERM	Older compound and use patents, largely mature
Ospemifene	Chlorinated triphenylethylene-related compound	Separate composition and method patents
Lasofoxifene	Tetrahydronaphthalene SERM	Separate composition and formulation estate

Bazedoxifene's distinctive commercial advantage was the combination of SERM activity with osteoporosis and menopausal applications. That commercial positioning generated separate patent questions for monotherapy, estrogen combinations, dosing and formulations.

Key Takeaways

U.S. Patent 5,998,402 is a broad substituted-indole compound patent.
Claims 44 and 45 are the most relevant claims for bazedoxifene and bazedoxifene acetate.
Claims 1, 3 and 4 create broad Markush coverage across aryl, alkoxy, hydroxy, halogen, aminoalkyl and nitrogen-ring substitutions.
Claim 105 covers conventional pharmaceutical compositions.
Claim 106 covers treatment or prevention of bone loss.
The patent is an expired or substantially exhausted original small-molecule patent and should not be treated as the sole current barrier to generic entry.
Biosimilar risk is irrelevant because bazedoxifene is a small molecule.
Current commercial risk must focus on later patents, Orange Book listings, Duavee combination claims, regulatory exclusivity and any unresolved ANDA litigation.
The supplied claims do not establish the identity of any current Paragraph IV challenger or settlement agreement.

FAQs

Is bazedoxifene acetate directly covered by U.S. Patent 5,998,402?

Yes. Claim 45 expressly covers the acetate salt of the azepane-based bazedoxifene structure, subject to construction of the issued claim and the patent's term.

Does a different bazedoxifene polymorph avoid the patent?

Not necessarily. A polymorph may avoid a narrowly drafted solid-state claim, but it would not ordinarily avoid an unexpired composition claim directed to the underlying active compound.

Is Duavee protected by the same patent as Viviant?

Not necessarily. Duavee contains conjugated estrogens and bazedoxifene and may be protected by later combination, formulation, dosing and method patents distinct from the original bazedoxifene compound patent.

Can a generic launch after expiration without filing Paragraph IV?

A generic applicant may use an expired-patent certification or another applicable FDA certification. The required pathway depends on the patents listed for the specific reference product and their status at the time of ANDA filing.

Does claim 106 cover osteoporosis treatment only?

No. The text covers treating or preventing bone loss in a mammal. The claim is not expressly limited to osteoporosis, a particular patient population, dose or route of administration.

References

United States Patent and Trademark Office. (1999). U.S. Patent No. 5,998,402: Indole compounds, pharmaceutical compositions and methods of use thereof.
U.S. Food and Drug Administration. (2013). Viviant (bazedoxifene acetate) prescribing information.
U.S. Food and Drug Administration. (2013). Duavee (conjugated estrogens/bazedoxifene) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0802183	⤷ Start Trial	PA2009007	Lithuania	⤷ Start Trial
European Patent Office	0802183	⤷ Start Trial	CA 2009 00035	Denmark	⤷ Start Trial
European Patent Office	0802183	⤷ Start Trial	91608	Luxembourg	⤷ Start Trial
European Patent Office	0802183	⤷ Start Trial	300416	Netherlands	⤷ Start Trial
European Patent Office	0802183	⤷ Start Trial	PA2009007,C0802183	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,998,402

Summary for Patent: 5,998,402